Friday, 20 November 2026 Search Subscribe
Laboratory apparatus for immunology research
Photograph: Linda Bartlett, National Cancer Institute, via Wikimedia Commons (public domain)

Gene therapy definitions to be rewritten so synthetic and genome editing treatments fit the rules

The Government confirmed on Thursday that the legal definition of a gene therapy medicinal product will be modernised, after 83 per cent of consultation respondents backed the change, so that certain synthetic therapies and genome editing treatments are regulated under the advanced therapies framework.

The legal definition of a gene therapy medicine is to be brought up to date with the science it governs. The Government confirmed on Thursday 19 November that it plans to modernise the definition of gene therapy medicinal products, so that certain synthetic gene therapies and novel genome editing treatments sit inside the established framework for advanced therapies. The proposals amend the Human Medicines Regulations 2012, and they take effect only after international notification procedures and parliamentary approval, through the secondary legislation the Medicines and Healthcare products Regulatory Agency says it now intends to bring forward.

The case for change is that the categories have aged. The definitions of advanced therapy medicinal products were first developed in 2007, for a field built on a smaller range of technologies. Therapies now in development can rest on synthetic genetic material, on new forms of genome editing and on highly engineered cells and tissues, and many of them do not fit neatly into the categories the 2012 Regulations set out. The consultation documents spell out three gaps in particular: the requirement that a gene therapy be biological in origin shuts out synthetic nucleic acid constructs that behave in the same way as biologically derived therapies, the focus on recombinant nucleic acids did not anticipate gene editing delivered through other systems, and the rule that the therapeutic effect must derive directly from the recombinant sequence leaves out products where genetic modification instead performs a safety or manufacturing function.

The replacement test is deliberately neutral about the technology used. Once the change is implemented, two routes lead to classification as a gene therapy medicinal product. The first is a medicine whose active ingredient carries nucleic acid, recombinant or synthetic in origin, that the body then transcribes or translates. The second is a medicine that works by editing the genome at one specific sequence. The regulator says this keeps continuity with the existing advanced therapy principles while capturing modern synthetic platforms and gene editing systems inside the framework, rather than leaving them at its edges.

Research being carried out in a microscopy laboratory
Photograph: Idaho National Laboratory, via Wikimedia Commons (CC BY 2.0)
Research in a microscopy laboratory. Under the new test, a medicine may qualify because its active ingredient carries nucleic acid that the body transcribes or translates, or because it edits the genome at a specific sequence. Archive photograph.
These proposals will address a gap in the current definition, providing a clearer route to licensing for certain synthetic gene therapies and greater certainty for developers about the regulatory requirements they need to meet.Julian Beach, Executive Director Operations at the MHRA, in the Government announcement of 19 November 2026

What does not change matters as much to developers as what does. The approval process and the standards for safety, quality and efficacy remain unchanged, and medicines that are already licensed will not need to be reclassified, so the reform is meant to remove classification uncertainty without disturbing products already on the market. The Government argues that greater certainty about how a medicine will be classified, and about the requirements it must meet, helps developers plan and supports investment in the UK life sciences sector.

The mandate for the change comes from a public consultation run jointly by the MHRA and the Department of Health in Northern Ireland. It opened UK wide on 11 May 2026 and closed on 22 June 2026, running for six weeks. In all, 48 responses arrived, from patient groups and professional bodies, from NHS organisations and academic institutions, and from companies in pharmaceuticals and biotechnology. Of those, 40 respondents, or 83 per cent, supported the proposed changes, while 5 respondents, or 10 per cent, either disagreed or strongly disagreed. Having weighed the responses, the two bodies concluded that stakeholder support was strong and set out their intention to proceed in the consultation outcome published alongside the announcement.

Scientists working in a laboratory
Photograph: Esculab, via Wikimedia Commons (CC0)
Scientists at work in a laboratory. Medicines already licensed will not need to be reclassified under the new definitions, and the standards for safety, quality and efficacy stay as they are. Archive photograph.

The announcement itself was made at a new regulatory gathering, the inaugural DIA-MHRA Global Summit, held in London on 16 and 17 November 2026 as part of London Life Sciences Week and hosted jointly by the MHRA and the Drug Information Association. The summit brought together international regulators, industry leaders, researchers, healthcare professionals and patient representatives. Julian Beach, the MHRA's Executive Director Operations, told the audience that the science behind gene therapy is moving quickly and the rules have to move with it. Certainty about classification, he argued, would draw investment into the sector and help promising new treatments reach patients sooner.

Filed under: Society, MHRA, gene therapy, medicines regulation, genome editing, life sciences, Human Medicines Regulations

Corrections
None to date. The Journal corrects errors promptly and transparently. Read our corrections policy.
British Journal
Staff reports
British JournalSociety